Iovance Biotherapeutics Valuation Multiples

Iovance Biotherapeutics Overview

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Founded

2007

HQ

Employees

975

Website

iovance.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $296M

EBITDA: ($328M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Iovance Biotherapeutics Financials

Iovance Biotherapeutics reported last 12-month revenue of $296M and negative EBITDA of ($328M).

In the same LTM period, Iovance Biotherapeutics generated $114M in gross profit, ($328M) in EBITDA losses, and had net loss of ($341M).

Iovance Biotherapeutics P&L

In the most recent fiscal year, Iovance Biotherapeutics reported revenue of $264M and EBITDA of ($351M).

Iovance Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Iovance Biotherapeutics Stock Performance

Iovance Biotherapeutics has current market cap of $2B, and enterprise value of $1B.

Iovance Biotherapeutics' stock price is $4.01.

Iovance Biotherapeutics Valuation Multiples

Iovance Biotherapeutics trades at 4.8x EV/Revenue multiple, and (4.3x) EV/EBITDA.

Iovance Biotherapeutics Financial Valuation Multiples

As of April 11, 2026, Iovance Biotherapeutics has market cap of $2B and EV of $1B.

Equity research analysts estimate Iovance Biotherapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Iovance Biotherapeutics has a P/E ratio of (4.8x).

Iovance Biotherapeutics Margins & Growth Rates

Iovance Biotherapeutics' revenue in the last 12 month grew by 42%.

Iovance Biotherapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.

Iovance Biotherapeutics' rule of 40 is (10%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Iovance Biotherapeutics' rule of X is 57% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Iovance Biotherapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Iovance Biotherapeutics M&A Activity

Iovance Biotherapeutics acquired XXX companies to date.

Last acquisition by Iovance Biotherapeutics was on XXXXXXXX, XXXXX. Iovance Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Iovance Biotherapeutics Investment Activity

Iovance Biotherapeutics invested in XXX companies to date.

Iovance Biotherapeutics made its latest investment on XXXXXXXX, XXXXX. Iovance Biotherapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).